Dong Fang Liu
Chief Tech/Sci/R&D Officer bei NUVATION BIO INC.
Vermögen: 21 840 $ am 31.03.2024
Aktive Positionen von Dong Fang Liu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NUVATION BIO INC. | Chief Tech/Sci/R&D Officer | 18.07.2022 | - |
Karriereverlauf von Dong Fang Liu
Ehemalige bekannte Positionen von Dong Fang Liu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| 3D MEDICINES INC. | Chief Tech/Sci/R&D Officer | 11.01.2019 | 01.03.2021 |
| CELGENE | Director/Board Member | - | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Ausbildung von Dong Fang Liu
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Toledo (Ohio) | Graduate Degree |
| Beijing Medical University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
| China | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NUVATION BIO INC. | Health Technology |
| 3D MEDICINES INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Börse
- Insiders
- Dong Fang Liu
- Erfahrung
